Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.

<h4>Background</h4>The Xpert MTB/RIF (Cepheid) non-laboratory-based molecular assay has potential to improve the diagnosis of tuberculosis (TB), especially in HIV-infected populations, through increased sensitivity, reduced turnaround time (2 h), and immediate identification of rifampici...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lesley E Scott, Kerrigan McCarthy, Natasha Gous, Matilda Nduna, Annelies Van Rie, Ian Sanne, Willem F Venter, Adrian Duse, Wendy Stevens
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2011
Materias:	Medicine R
Acceso en línea:	https://doaj.org/article/cd6aa2b03e1542fd860e52de286df21d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cd6aa2b03e1542fd860e52de286df21d
record_format	dspace
spelling	oai:doaj.org-article:cd6aa2b03e1542fd860e52de286df21d2021-11-18T05:41:45ZComparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.1549-12771549-167610.1371/journal.pmed.1001061https://doaj.org/article/cd6aa2b03e1542fd860e52de286df21d2011-07-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21814495/pdf/?tool=EBIhttps://doaj.org/toc/1549-1277https://doaj.org/toc/1549-1676<h4>Background</h4>The Xpert MTB/RIF (Cepheid) non-laboratory-based molecular assay has potential to improve the diagnosis of tuberculosis (TB), especially in HIV-infected populations, through increased sensitivity, reduced turnaround time (2 h), and immediate identification of rifampicin (RIF) resistance. In a prospective clinical validation study we compared the performance of Xpert MTB/RIF, MTBDRplus (Hain Lifescience), LightCycler Mycobacterium Detection (LCTB) (Roche), with acid fast bacilli (AFB) smear microscopy and liquid culture on a single sputum specimen.<h4>Methods and findings</h4>Consecutive adults with suspected TB attending a primary health care clinic in Johannesburg, South Africa, were prospectively enrolled and evaluated for TB according to the guidelines of the National TB Control Programme, including assessment for smear-negative TB by chest X-ray, clinical evaluation, and HIV testing. A single sputum sample underwent routine decontamination, AFB smear microscopy, liquid culture, and phenotypic drug susceptibility testing. Residual sample was batched for molecular testing. For the 311 participants, the HIV prevalence was 70% (n = 215), with 120 (38.5%) culture-positive TB cases. Compared to liquid culture, the sensitivities of all the test methodologies, determined with a limited and potentially underpowered sample size (n = 177), were 59% (47%-71%) for smear microscopy, 76% (64%-85%) for MTBDRplus, 76% (64%-85%) for LCTB, and 86% (76%-93%) for Xpert MTB/RIF, with specificities all >97%. Among HIV+ individuals, the sensitivity of the Xpert MTB/RIF test was 84% (69%-93%), while the other molecular tests had sensitivities reduced by 6%. TB detection among smear-negative, culture-positive samples was 28% (5/18) for MTBDRplus, 22% (4/18) for LCTB, and 61% (11/18) for Xpert MTB/RIF. A few (n = 5) RIF-resistant cases were detected using the phenotypic drug susceptibility testing methodology. Xpert MTB/RIF detected four of these five cases (fifth case not tested) and two additional phenotypically sensitive cases.<h4>Conclusions</h4>The Xpert MTB/RIF test has superior performance for rapid diagnosis of Mycobacterium tuberculosis over existing AFB smear microscopy and other molecular methodologies in an HIV- and TB-endemic region. Its place in the clinical diagnostic algorithm in national health programs needs exploration. Please see later in the article for the Editors' Summary.Lesley E ScottKerrigan McCarthyNatasha GousMatilda NdunaAnnelies Van RieIan SanneWillem F VenterAdrian DuseWendy StevensPublic Library of Science (PLoS)articleMedicineRENPLoS Medicine, Vol 8, Iss 7, p e1001061 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R
spellingShingle	Medicine R Lesley E Scott Kerrigan McCarthy Natasha Gous Matilda Nduna Annelies Van Rie Ian Sanne Willem F Venter Adrian Duse Wendy Stevens Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.
description	<h4>Background</h4>The Xpert MTB/RIF (Cepheid) non-laboratory-based molecular assay has potential to improve the diagnosis of tuberculosis (TB), especially in HIV-infected populations, through increased sensitivity, reduced turnaround time (2 h), and immediate identification of rifampicin (RIF) resistance. In a prospective clinical validation study we compared the performance of Xpert MTB/RIF, MTBDRplus (Hain Lifescience), LightCycler Mycobacterium Detection (LCTB) (Roche), with acid fast bacilli (AFB) smear microscopy and liquid culture on a single sputum specimen.<h4>Methods and findings</h4>Consecutive adults with suspected TB attending a primary health care clinic in Johannesburg, South Africa, were prospectively enrolled and evaluated for TB according to the guidelines of the National TB Control Programme, including assessment for smear-negative TB by chest X-ray, clinical evaluation, and HIV testing. A single sputum sample underwent routine decontamination, AFB smear microscopy, liquid culture, and phenotypic drug susceptibility testing. Residual sample was batched for molecular testing. For the 311 participants, the HIV prevalence was 70% (n = 215), with 120 (38.5%) culture-positive TB cases. Compared to liquid culture, the sensitivities of all the test methodologies, determined with a limited and potentially underpowered sample size (n = 177), were 59% (47%-71%) for smear microscopy, 76% (64%-85%) for MTBDRplus, 76% (64%-85%) for LCTB, and 86% (76%-93%) for Xpert MTB/RIF, with specificities all >97%. Among HIV+ individuals, the sensitivity of the Xpert MTB/RIF test was 84% (69%-93%), while the other molecular tests had sensitivities reduced by 6%. TB detection among smear-negative, culture-positive samples was 28% (5/18) for MTBDRplus, 22% (4/18) for LCTB, and 61% (11/18) for Xpert MTB/RIF. A few (n = 5) RIF-resistant cases were detected using the phenotypic drug susceptibility testing methodology. Xpert MTB/RIF detected four of these five cases (fifth case not tested) and two additional phenotypically sensitive cases.<h4>Conclusions</h4>The Xpert MTB/RIF test has superior performance for rapid diagnosis of Mycobacterium tuberculosis over existing AFB smear microscopy and other molecular methodologies in an HIV- and TB-endemic region. Its place in the clinical diagnostic algorithm in national health programs needs exploration. Please see later in the article for the Editors' Summary.
format	article
author	Lesley E Scott Kerrigan McCarthy Natasha Gous Matilda Nduna Annelies Van Rie Ian Sanne Willem F Venter Adrian Duse Wendy Stevens
author_facet	Lesley E Scott Kerrigan McCarthy Natasha Gous Matilda Nduna Annelies Van Rie Ian Sanne Willem F Venter Adrian Duse Wendy Stevens
author_sort	Lesley E Scott
title	Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.
title_short	Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.
title_full	Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.
title_fullStr	Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.
title_full_unstemmed	Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.
title_sort	comparison of xpert mtb/rif with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high hiv prevalence setting: a prospective study.
publisher	Public Library of Science (PLoS)
publishDate	2011
url	https://doaj.org/article/cd6aa2b03e1542fd860e52de286df21d
work_keys_str_mv	AT lesleyescott comparisonofxpertmtbrifwithothernucleicacidtechnologiesfordiagnosingpulmonarytuberculosisinahighhivprevalencesettingaprospectivestudy AT kerriganmccarthy comparisonofxpertmtbrifwithothernucleicacidtechnologiesfordiagnosingpulmonarytuberculosisinahighhivprevalencesettingaprospectivestudy AT natashagous comparisonofxpertmtbrifwithothernucleicacidtechnologiesfordiagnosingpulmonarytuberculosisinahighhivprevalencesettingaprospectivestudy AT matildanduna comparisonofxpertmtbrifwithothernucleicacidtechnologiesfordiagnosingpulmonarytuberculosisinahighhivprevalencesettingaprospectivestudy AT anneliesvanrie comparisonofxpertmtbrifwithothernucleicacidtechnologiesfordiagnosingpulmonarytuberculosisinahighhivprevalencesettingaprospectivestudy AT iansanne comparisonofxpertmtbrifwithothernucleicacidtechnologiesfordiagnosingpulmonarytuberculosisinahighhivprevalencesettingaprospectivestudy AT willemfventer comparisonofxpertmtbrifwithothernucleicacidtechnologiesfordiagnosingpulmonarytuberculosisinahighhivprevalencesettingaprospectivestudy AT adrianduse comparisonofxpertmtbrifwithothernucleicacidtechnologiesfordiagnosingpulmonarytuberculosisinahighhivprevalencesettingaprospectivestudy AT wendystevens comparisonofxpertmtbrifwithothernucleicacidtechnologiesfordiagnosingpulmonarytuberculosisinahighhivprevalencesettingaprospectivestudy
_version_	1718424880064495616

Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.

Ejemplares similares